{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:30:12Z","timestamp":1790119812164,"version":"4.0.1"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review summarizes the current evidence on inflammatory arthritis following cancer treatment with immune checkpoint inhibitors (ICI), and the effects of these therapies in patients with preexisting autoimmune arthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>As the use of ICI for cancer therapy continues to expand, a myriad of immune-related adverse events (irAE) caused by these therapies are being recognized. Arthritis has been increasingly reported as a de novo irAE, presenting sometimes as a well defined disorder, such as rheumatoid arthritis or psoriatic arthritis, and in other occasions as undifferentiated monoarthritis, oligoarthritis, or polyarthritis. Remitting seronegative symmetric synovitis with pitting edema (RS3PE) and tenosynovitis have also been reported. Most published cases are reported as mild to moderate in severity. The most common treatment for arthritis has been systemic corticosteroids, although several patients have been treated with traditional disease-modifying antirheumatic drugs (DMARD), and a few, with biologic DMARD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Arthritis following ICI therapy is pleomorphic. Prompt identification and treatment are imperative to achieve optimal outcomes. Management should be multidisciplinary, including rheumatologists and oncologists, to ensure prompt symptomatic and functional management and continuation of cancer therapy as appropriate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000601","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T19:44:47Z","timestamp":1553111087000},"page":"293-299","source":"Crossref","is-referenced-by-count":54,"title":["Arthritis risk with immune checkpoint inhibitor therapy for cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"Xerxes","family":"Pundole","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, USA"},{"name":"Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2017-0108","article-title":"Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review","volume":"9","author":"Abdel-Rahman","year":"2017","journal-title":"Immunotherapy"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy- implications for rheumatology","volume":"43","author":"Cappelli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2014.00276","article-title":"Th17 cells in cancer: the ultimate identity crisis","volume":"5","author":"Bailey","year":"2014","journal-title":"Front Immunol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/08916934.2016.1166214","article-title":"New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis","volume":"49","author":"Karczewski","year":"2016","journal-title":"Autoimmunity"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10067-016-3263-4","article-title":"IL-23\/IL-17 axis in spondyloarthritis-bench to bedside","volume":"35","author":"Raychaudhuri","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrrheum.2015.128","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol Immunol"},{"issue":"(suppl 2)","key":"R19-20230828","first-page":"P444","article-title":"Inflammatory arthritis induced by the use of checkpoint inhibitors for immunotherapy of cancer","volume":"5","author":"Abdel-Wahab","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"R26-20230828","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","author":"Smith","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/CJI.0000000000000174","article-title":"Two cases of sinusitis induced by immune checkpoint inhibition","volume":"40","author":"Dein","year":"2017","journal-title":"J Immunother"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.ejhg.5201214","article-title":"Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus","volume":"12","author":"Barreto","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00393-014-1415-y","article-title":"Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility","volume":"74","author":"Lee","year":"2015","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.humimm.2014.02.020","article-title":"CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis","volume":"75","author":"Lee","year":"2014","journal-title":"Hum Immunol"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0961203308093923","article-title":"Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis","volume":"18","author":"Lee","year":"2009","journal-title":"Lupus"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13000-014-0157-0","article-title":"The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis","volume":"9","author":"Li","year":"2014","journal-title":"Diagn Pathol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1468-3083.2009.03087.x","article-title":"Association between the PD1.3A\/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis","volume":"23","author":"Liu","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-065X.2008.00639.x","article-title":"CTLA-4: a key regulatory point in the control of autoimmune disease","volume":"223","author":"Scalapino","year":"2008","journal-title":"Immunol Rev"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/1756-185X.12705","article-title":"The association between CTLA-4 (+49 A\/G) polymorphism and susceptibility to ankylosing spondylitis: a meta-analysis","volume":"19","author":"Wu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R39-20230828","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","author":"Cappelli","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"(suppl 10)","key":"R40-20230828","article-title":"Traditional disease modifying anti-rheumatic drugs (tDMARDs), hydroxychloroquine (HCQ) and\/or sulfasalazine (SSZ), are rapidly effective in immune checkpoint inhibitors-induced inflammatory arthritis [abstract]","volume":"69","author":"Alperin","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"(suppl 9)","key":"R41-20230828","doi-asserted-by":"crossref","first-page":"ix108","DOI":"10.1093\/annonc\/mdx621.063","article-title":"Severe immune-related adverse events (irAE) induced by nivolumab at our institution","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Ann Oncol"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narvaez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"pii: 13030\/qt12n4m6pm","DOI":"10.5070\/D3238036018","article-title":"A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy","volume":"23","author":"Elosua-Gonzalez","year":"2017","journal-title":"Dermatol Online J"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.semarthrit.2017.03.003","article-title":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab","volume":"47","author":"Gauci","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"(2 Suppl 1)","key":"R45-20230828","first-page":"578","article-title":"Not your typical joint pain: a case of extensive polyarthritis secondary to immune checkpoint in-hibitor use","volume":"33","author":"In","year":"2018","journal-title":"J Gen Intern Med"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10067-018-4035-0","article-title":"Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment","volume":"37","author":"Inamo","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R47-20230828","article-title":"Nivolumab-induced polyarthritis","volume":"2017","author":"Kodama","year":"2017","journal-title":"BMJ Case Rep"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13256-018-1579-1","article-title":"Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report","volume":"12","author":"Ngo","year":"2018","journal-title":"J Med Case Rep"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/RHU.0000000000000525","article-title":"Autoimmune polyarthritis induced by cancer immunotherapy with checkpoint inhibitor","volume":"23","author":"Quresh","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"R52-20230828","first-page":"182","article-title":"Psoriatic arthritis due to nivolumab administration a case report and review of the literature","volume":"23","author":"Sapalidis","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fonc.2018.00409","article-title":"Inflammatory arthritis induced by pembrolizumab in a patient with head and neck squamous cell carcinoma","volume":"8","author":"Spathas","year":"2018","journal-title":"Front Oncol"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jtho.2018.01.027","article-title":"Atezolizumab after nivolumab-induced inflammatory polyarthritis: can anti-PD-L1 immunotherapy be administered after anti-PD-1-related immune toxicities?","volume":"13","author":"Swami","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1111\/1346-8138.13840","article-title":"Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"issue":"(suppl 4)","key":"R57-20230828","first-page":"152","article-title":"Large joint inflammatory arthritis induced by pembrolizumab in metastatic melanoma","volume":"13","author":"Wong","year":"2017","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"issue":"(Supplement 10)","key":"R60-20230828","doi-asserted-by":"crossref","first-page":"x135","DOI":"10.1093\/annonc\/mdx671.030","article-title":"A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with nonsmall cell lung cancer","volume":"28","author":"Fukui","year":"2017","journal-title":"Ann Oncol"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"key":"R62-20230828","article-title":"Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management","volume":"2018","author":"Lim","year":"2018","journal-title":"J Skin Cancer"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with antiprogrammed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"key":"R64-20230828","first-page":"190","article-title":"Management of rheumatological immune related adverse events in melanoma patients treated with antiprogrammed cell death (PD) 1 antibodies","volume":"31","author":"Mitchell","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/jdv.14633","article-title":"Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab","volume":"32","author":"Mohr","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/jdv.14486","article-title":"Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?","volume":"32","author":"Quereux","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/kex470","article-title":"Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events","volume":"57","author":"Albayda","year":"2018","journal-title":"Rheumatology"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"(suppl 2)","key":"R69-20230828","first-page":"55","article-title":"Immune-related toxicity associated with immunotherapy in solid organ malignancies: experience at a tertiary referral center","volume":"13","author":"Ariyapperuma","year":"2017","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of antiprogrammed death 1 antibodies in patients with cancer and preexisting autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with preexisting autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/CMR.0000000000000387","article-title":"The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis","volume":"27","author":"Puri","year":"2017","journal-title":"Melanoma Res"},{"key":"R74-20230828","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R75-20230828","first-page":"8095601","article-title":"Immunotherapy for metastatic melanoma with right atrial involvement in a patient with rheumatoid arthritis","volume":"2017","author":"Benson","year":"2017","journal-title":"Case Rep Oncol Med"},{"issue":"(suppl 1)","key":"R76-20230828","first-page":"64","article-title":"Treatment of Merkel cell carcinoma with pembrolizumab in a patient with psoriasis and psoriatic arthritis","volume":"177","author":"Murphy","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201905000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:34:14Z","timestamp":1693200854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201905000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000601","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}